purpose make world smarter happier richer founded motley fool financial service company dedicated making world smarter happier richer motley fool reach million people every month premium investing solution free guidance market analysis foolcom toprated podcasts nonprofit motley fool foundation purpose make world smarter happier richer founded motley fool financial service company dedicated making world smarter happier richer motley fool reach million people every month premium investing solution free guidance market analysis foolcom toprated podcasts nonprofit motley fool foundation mrvi earnings call period ending december image source motley fool maravai lifesciences mrvi q earnings callfeb pm etcontents prepared remark question answer call participant prepared remark operatorgood afternoon thank standing time would like welcome everyone q maravai lifesciences earnings conference call operator instruction would like turn conference deb hart head investor relation please go aheaddeb hart head investor relation good afternoon everyone thanks joining u fourth quarter yearend earnings call press release slide accompany today call posted website available investorsmaravaicom see agenda today slide trey first provide business update kevin review financial result guidance drew burch president nucleic acid production join call questionandanswer session following prepared remark remind management make forwardlooking statement refer gaap nongaap financial measure today call possible actual result could differ management expectation refer slide detail forwardlooking statement use nongaap financial measuresour justissued press release provides reconciliation directly comparable gaap measure please also refer maravais sec filing additional information risk uncertainty may impact operating result performance financial condition turn call trey trey martin chief executive officer thank deb good afternoon everyone appreciate join u call today let u start financial result slide today reported million revenue full year adjusted ebitda million fourth quarter result million revenue stronger anticipated due outperformance base nucleic acid production segment specifically cleancap custom chemistry turning slide nucleic acid production segment revenue million q includes estimated million covid cleancap revenue full year total nucleic acid production revenue million base nap revenue million covid cleancap revenue million year biologics safety testing segment contributed million q million full year q base noncovid revenue companywide million q total million exit fiscal year begin entering new era maravai referring maravai let put context slide many know maravai originally founded nearly year ago carl hull eric tardif along support backing gtcr maravai private equitybacked company strategy consolidate differentiated founderbased life science tool company industryleading technology strong brand maravai acquired company including trilink biotechnology cygnus technology glen research acquisition serve unique niche industry rollout strategy extremely successful pandemic hit entered new phase many customer pivoted focus develop covid vaccine including biontech already using trilink cleancap technology mrna van therapeutic development maravai primarily focused scale nucleic acid product specifically cleancap product needed meet global pandemic vaccine demand scaled production cleancap gram kilo transition ruo grade gmp quality move running hour shift seven day week important period maravai allowed u prove ability scale demonstrate cleancaps clinical potential form billion safe effective vaccine dos period decided company public november throughout pandemic period able ledge profitability strong cash flow reinvest scaling operation expanding footprint finished buildout wateridge facility well ahead plan started building flanders gmp facility moved biologic safety testing team brand new stateoftheart facility leland north carolina also made additional complementary acquisition including mychem nucleic acid chemistry leader alphazyme specialized enzyme also part nucleic acid production segment incredible amount capability capacity infrastructure came pandemic era serve u today throughout next decade let u turn slide maravai maravai postpandemic phase company new normal capability infrastructure addition came pandemicera investment give u foundation exceptional operating leverage going forward going replace covid vaccine revenue single program single customer focused preparation entire mrna production workflow building capability emerging adjacent product service area differentiate diversify business longterm sustainable growth fact believe diversified customer base last five year moment organized two main reporting segment nucleic acid production biologics safety testing within nap trilink biotechnology glen research alphazyme bst brand including mockv technology acquisition brand strong history customer relationship act product supplier technical expert consult help customer development scaleup challenge acquisition remain key component strategy moving forward believe right market specifically mrna platform well crispr gene editing cell gene therapy start discovery market business unique ability translate discovery product service way gmp value proposition winning customer discovery supporting commercialization stronger ever maravai leading innovator key role future genomic personalized medicine believe continue differentiate technology leader first choice partner customer think privileged opportunity part next generation medicine goal helping improve human health turning slide let share update thirdparty analysis commissioned specific cleancap program may recall first exercise february identified preclinical clinical trial using cleancap rate research december saw overall growth program annual refresh work recently completed identified program use cleancap new program last month period includes preclinical commercialized program variety different condition note different cleancap analog used production three different mrna product received full regulatory approval really exciting cleancap ag primalmethyl pfizer biontech vaccine cleancap au used selfamplifying vaccine approved use japan cleancap ag also vaccine approved use marketed japan looking pipeline clinical phase note three four identified program preclinical early discovery support strategy win discovery grow customer advance clinic approval true cleancap product service let u turn slide specific cleancap analysis growth mrna pipeline seen across multiple modality shown left ring chart multiple application including cancer vaccine infectious disease vaccine cell therapy use mrna reflects widespread interest big pharma mrna platform technology foreshadows believe sustained future investment field heat map right show top disease target program cancer infectious disease within infectious disease program covid related really pleased latest data twofold first see notable increase program headed clinic discovery pipeline accelerating second phase program moved clinic three five year ago use cleancap le often phase program moved clinic last year suggesting strategy win discovery playing intend support customer lifespan developmental program one important note data yet reflect cleancap introduced last may longterm history mrna manufacturing process provides smooth path early phase customer looking way move quickly scale clinical manufacturing without tech transfer provide customer faster route plugging platform workflow technology called cleanscript cleanscript platform get heart customer need like reducing doublestranded rna manufacturing process instead trying remove downstream working established partner trilink reduces time risk clinical stage production specific trilink q provided limited set customer early access smallscale mrna offering screening sequence optimization received multiple order industryleading organization early evidence right track evolve mrna portfolio enable early stage discovery program offering expect expand key screening market upstream current marketplace providing crossselling opportunity adding customer base launching cleancap last year discovery customer working several shared intent incorporate preclinical clinical study next several quarter reinforcing strategy mining discovery also pleased share alphazyme sell enzyme ibt process mrna production believe gain market share share wallet continuous innovation new product development exceptional service truly unique commercial position market large number biopharma innovator size come u first earliest stage program product service customer pipeline reflects future contour industry let u move slide another record year fda approval development pipeline meaningfully higher point history fact fda approved nearly novel drug putting back pace historically level fda approved new innovative therapy commenting active ingredient molecule previously approved agency also approved new cell gene therapy addition novel drug seen news hear commentary peer fda increasing staff aiming improve drug approval process expedite drug approval orphan disease particular establishing accelerated approval gene therapy bodes well product service offering future work support customer program discovery latephase development let u move slide facility update poised achieve latephase manufacturing capability cgmp mrna continue acceleration innovation across business specific flanders site several request gmp cleancap plan start producing flanders midyear flanders received first booking customer produce latestage mrna drug substance customer showing strong interest pipeline indenabling clinical material strong move made early upgrade commercial team facility getting u front customer rfp process customer operational readiness plan technical manufacturing team meet clinical time line flanders facility coming online new analytical science center excellence san diego wellpositioned cost partner choice number mrna drug moving clinical phase continues accelerate commercial strategy becky buzzeos leadership win discovery right product service continue support unique need mrna cell gene therapy customer clinical development program full commercialization strategy also includes fostering key academic industry partnership enhance innovation accelerate market adoption latest technology return growth requires protect grow unique core capability currently business also market u disrupt differentiate evolution enzyme capability alzheimer mockv viral clearance testing cygnus custom mrna trilink discovery look beyond need rice product service early stage program greater ever let u move slide update actual property recent patent issued china canada reinforce global strength protection trilink intellectual property adding new jurisdiction enforcement cleancap patent estate already includes united state european union australia japan korea hong kong hold ip cleancap material method major market across globe importantly drug developer china expanded access licensed authentic cleancap technology please turn slide exciting development maravai signed key license q strengthened position advance number cleancap mrna program clinical trial enabled fujifilm toyama chemical cdmo ability manufacture cleancap mrna enable global customer access incountry cdmo choice japan agreement includes form cleancap including latest cleancap continue focus new product innovation glen research highquality provider fluorophores quencher label modifier oligonucleotide synthesis published glen report glen report publication since serf wellregarded resource many scientist engaged dna rna research oligonucleotide synthesis new phosphoramidite product announced latest issue including mam mam phosphoramidite monomer found cleancap affording access modification rna oligonucleotide future biologic study cygnus team recently signed strategic partnership dyadic provide new c host cell protein inaudible extending product leadership hcp detection kit qualified many drug substance inprocess sample providing specificity sensitivity detect c host cell protein impurity reproducibility support downstream purification monitoring product lot release regulatory compliance cygnus continues shine cell gene therapy market supporting cart gene cell therapy approval lot release cygnus drug developer way process development commercialization turning slide saw press release introducing revenue guidance million million mentioned earlier call believe revenue diversified since prior pandemic top customer represented third overall business pandemic top customer jumped represent total revenue last year top customer accounted le overall revenue believe top revenue concentration continue decline time expand customer base increase product offering take advantage crossselling opportunity believe continue build stronger customer intimacy drive sustainable durable growth maravai unique position provide concierge level experience customer make easy business u whether enabling faster turnaround time incorporating novel chemistry creating flexible partnership viewed highquality experience owner manage challenging technology many others industry equipped could excited maravai know continue make significant contribution improving human health energized new year renewed focus supporting customer accelerate discovery provide lifechanging medicine patient worldwide ask kevin cover fourthquarter fullyear performance along detail model assumption kevinkevin herde executive vice president chief financial officer thanks trey good afternoon everyone trey mentioned pleased finished ahead expectation excited move forward briefly cover financial result fourth quarter full year discus financial guidance get started result core operation want address large gaapbased nonoperating line item slide likely drew attention press release issued earlier today result shifting gaapbased pretax loss assessing forwardlooking gaap book income projection recognized valuation allowance deferred tax asset yearend recent history pretax loss considered significant piece objective evidence difficult overcome limit ability consider subjective future growth projection thus consultation technical accounting tax advisor believe appropriate establish full valuation allowance deferred tax asset given upc structure nature deferred tax asset predominantly recognized result ipo subsequent exchange generally partial valuation allowance available additionally longterm tax receivable agreement tra related liability tied usage deferred tax asset created via fc structure also removed liability gaapbased financial statement net impact item noncash nonebitda nonoperating gaap tax expense million establish full valuation allowance deferred tax asset corresponding million noncash nonebitda nonoperating gaap income gain tied relief tra liability many understand nature liability approximately underlying deferred tax asset typical upc structure conclude matter underlying deferred tax asset still available company utilize reduce taxable income future may able release valuation allowance gaap pretax income substantiated extent deferred tax asset utilized corresponding payment approximately benefit owner tax deferred agreement made include tra liability time release valuation allowance ask note gaapbased result book loss primarily due extent noncash charge depreciation amortization tied accounting acquisition facility buildouts well stockbased compensation charge question technical matter happy take later time focus call operating result maravai financial result quarter slide gaap net loss controlling interest million fourth quarter compare net income million fourth quarter gaap net loss year million compared income million noted consolidated state operation incurred gaapbased charge quarter million associated previously announced cost restructuring action moving slide adjusted ebitda nongaap measure million q compared million q adjusted ebitda margin q expectation quarter result higherthananticipated revenue quarter efficiency initiating cost restructure also benefited q adjusted ebitda year million adjusted ebitda margin high end last updated fullyear guidance adjusted ebitda million million discus ebitda segment slide moving slide basic diluted loss per share fourth quarter driven primarily net impact gaap noncash nonoperating charge associated net impact deferred tax asset valuation allowance expense change tra liability adjusted fully diluted eps nongaap measure share year eps metric basic diluted loss per share adjusted fully diluted eps nongaap measure per share moving forward yearend balance sheet cash flow financial metric slide ended year million cash million longterm debt resulting million net cash position adjusted free cash flow million quarter million full year calculation adjusted free cash flow nongaap measure based adjusted ebitda le capital expenditure million million quarter respectively million million fiscal year respective fiscal year generated million cash flow operation strong operational cash flow invested million expanding offering capability support future growth vector acquisition alphazyme investment flanders gmp facility includes capital expenditure net total million depreciation amortization ended year million line expectation previous guidance interest expense net interest income ended year million line expectation previous guidance represents effective interest rate year reflecting strong execution treasury operation stockbased compensation noncash charge million year also line previous guidance range ended million class share outstanding million class b share outstanding total million share outstanding yearend fully converted basis fully diluted weighted average share count also million share note total class plus class b share outstanding end following ipo million share million share end thus total share declined past year result bifurcated ownership structure cash accumulate topco result equalization tax distribution utilized effectively retire b unit outstanding increasing level class ownership transaction appeared conjunction acquisition alphazyme q effectively used around million cash reduce overall class e share offset dilution associated stock option restricted stock issuance employee director maravai since ipo leading reduction overall share outstanding past threeplus year simply put issued equity compensation seen noncash stockbased compensation charge increased annually also reduced total share outstanding virtue tax distribution mechanism whereby topco used excess cash received retire total share outstanding next slide discussion segment performance quarter nucleic acid production segment includes discovery gmp product service market trilink glen research alphazyme brand revenue fourth quarter million adjusted ebitda million margin year revenue nap segment million adjusted ebitda million margin included revenue fourth quarter estimate million revenue associated cleancap covidrelated vaccine demand brings total estimate cleancap covidrelated vaccine demand million line expectation previous guidance statement slide biologics safety testing segment includes product sickness brand revenue million fourth quarter adjusted ebitda million margin year revenue segment million adjusted ebitda million margin detailed segment result combined adjusted ebitda operating segment prior corporate shared service million combined margin clearly highlighting financial strength health core operational segment corporate shared service expense impacting total adjusted ebitda includes centralized function human resource finance accounting legal incremental expense associated public company totaled million quarter million year getting financial expectation slide guiding total revenue range million million breaking anticipated revenue segment see nucleic acid production segment midpoint mostly due anticipated decline highvolume gmp cleancap demand see biologic safety testing business achieving low midsingledigit growth enter maravai era longer carving estimate covidrelated cleancap guidance attempting estimate quarterly annual basis prospectively understand customer use gmp cleancap variety end us including supporting commercially approved vaccine research development program cleancap platform technology indicationspecific thus fungible hand customer guidance consider around million fiscal year contractual noncancelable gmp cleancap unit made customer cadence estimated revenue seen quarter past year le impact covidrelated cleancap varying annual total little bit variability year look revenue see first quarter carrying revenue first half year carrying total year see second half weighting slightly higher first half consistent historical variability consistent many peer outlook moving rest pl track realize previously targeted cost reduction million twothirds tied reduction labor force san diego base nucleic acid production corporate headquarters substantially completed first quarter targeted reduction partially offset annual cost increase associated remaining ongoing labor force focused investment commercial rd team drive organic growth overall expect gross margin flat slightly lower level based unfavorable product mix compared rd sale marketing expense estimated slightly absolute dollar basis reflecting ongoing investment area ga expense expected absolute basis versus overall estimate adjusted ebitda margin see adjusted eps range per share per share loss guidance also contemplates following expectation interest expense net interest income million million depreciation amortization million million equitybased compensation show reconciling item gaap nongaap ebitda million fully converted share count million adjusted effective tax rate lastly discussed outfitting final set flanders facility first half result u substantially complete facility invest back needed support business foreseeable future anticipate total net capital expenditure ship million million total subsequent completion mainly first half anticipate capital expenditure moving annual maintenance growth investment closer total revenue time turn call back treytrey martin chief executive officer wrap slide believe transitioned challenging maravai new normal poised solid diversified new combo vaccine cell gene therapy battling cancer believe transformative impact mrna global human health accelerate believe playing right target market strong leadership position building product service portfolio expanding strong brand strategically important highvalue area support genomic medicine committed building strong foundation long term sustainable profitable growth focus innovation scaling commercial organization leveraging new manufacturing scale inorganic growth opportunity incredible opportunity still ahead u participate next generation medicine going better treat case literally cure disease fuel team every single day maravai proud key role customer partner employee playing making happen finally thank attention investor thank trust support look forward continued collaboration around fulfilling mission coming year would like turn call back operator open line question question answer operatorthank operator instruction first question come line matt larew william blair line openmatt larew william blair company analyst hey good afternoon thank taking question wanted ask guidance first would sort top line referenced think million noncancelable order whole visibility issue past year year half curious thought constructing guidance year difference way thought approaching communicated guidance internal expectation see end market improvement general thought sort guidepost around guidekevin herde executive vice president chief financial officer yes sure matt thanks kevin take look think feel good guidance range think sit today versus saying overall percentage revenue see either recognized course year sitting po sitting contractual commitment like mentioned higher put u good spot near fullyear guidance closer third probably year ago give u conviction good grasp full year incorporated guidancematt larew william blair company analyst ok ebitda guide think midpoint sort margin revenue mix around million reported million fourth quarter recognizing thing like incentive comp reset first quarter curious look picture annualization q full relative midpoint guide maybe help u understand moving part beyond top line therekevin herde executive vice president chief financial officer yes well think take time midrange ebitda get million relatively consistent ended full year see certainly step revenue versus ended midpoint guidance big component also tell put cost action benefit probably tune around million fourth quarter million target yearoveryear benefit million half coming due lower revenue midpoint remainder thing one mentioned normalization compensation practice certainly continued investment commercial rd sit today sale head end concerted focus u particularly work maravai strong sale force reinvestment move forward relates margin cadence going see continued variability quarterbyquarter think see second third quarter ebitda margin midteens low revenue certainly given implied guidance first quarter based first quarter carrying roughly full year million number q expect ebitda margin first quarter relatively consistent midteens sort level increasing done historically key toggle margin expansion really top line continue see margin expansion topline growth moving fullyear estimate matt larew william blair company analyst ok thank youkevin herde executive vice president chief financial officer thanks mattoperatorour next question come line justin bower deutsche bank please go aheadjustin bower deutsche bank analyst yes good afternoon mute sorry wanted take step back high level talk demand environment evolved let u say last three six month look like sort calling inflection bit return growth strip covid cleancap wanted get sense sort driver behind interesting pointtrey martin chief executive officer yes thanks trey seeing would say first foremost willingness make binding commitment something obviously welcome chain identified discussed material coming period well pandemic period really intensely weighted toward heavy customer large order coming nice diversification growing number customer significantly seeing demand course smaller po smaller check ultimately lead much diversified would say stable predictable business transition would say demand seeing customer come unfortunately massive customer pandemic era also seen recommitment finding forecast maybe hand drew little colordrew burch president nucleic acid production yes thanks trey think trey described well annualized pandemicera commitment move past seen greater diversity customer think chart trey showed number clinical trial using cleancap speaks dynamic see number continuing go pretty significant rate replace larger commitment broader diversity customer think inaudible well futurejustin bower deutsche bank analyst maybe quick followup sort shelf life process validate efficacy cleancap question get lot guess wide range estimate would like get perspective thatdrew burch president nucleic acid production yes sure drew take customerdriven decision choose use inventory support customer retest date also retesting service pleased cleancap held well stability standpoint customer work make decision want manage inventoriesjustin bower deutsche bank analyst thank youoperatorour next question come line catherine schulte baird please go aheadcatherine schulte great thanks question prepared remark mentioned larger portion program entering phase last year used cleancap versus set year ago guess number term portion program entering phase last year utilize cleancap try get sense market sharetrey martin chief executive officer table asking number phase program end last year versus year total phase end total phase end catherine schulte ok resting mentioned larger cleancap used frequently program entering phase like percent phase utilized cleancap thatkevin herde executive vice president chief financial officer yes yes catherine schulte ok great helpful maybe first quarter guide implies decent sequential step revenue think outlook biologic safety testing versus nucleic acid production first quarter numberkevin herde executive vice president chief financial officer yes anticipated decline versus fourth quarter sequentially catherine going nap segment lot tied highvolume gmp cleancap actually see biologic safety testing stepping first quarter lot historically strong first quarter performance think see step bst q offset nap coming predominantly due highvolume gmp cleancap pattern seeing catherine schulte right great thank youoperatorour next question come line michael ryskin bank america please go aheadmike ryskin bank america merrill lynch analyst great thanks guy got couple quick question appreciate qa one million contractual know also said really want talk still want make sure thinking correctly million million believe million million contractual got anything say term end want make sure modeling correctly roll could pretty meaningful headwind come end got followupkevin herde executive vice president chief financial officer yes well think know license supply agreement work customer kind rolling annual rolling month forwardlooking forecast right certainly sit today comfortable guidance speaking related commitment go year working customer roll forward certainly better mean sort mechanism work right sticking sort clear view todaymike ryskin bank america merrill lynch analyst beautiful thenkevin herde executive vice president chief financial officer sorry say last year number publicly sharing carveout covidspecific large committed program number forecast beforemike ryskin bank america merrill lynch analyst ok yes followup question going ask fujifilm partnership gotten bunch question last couple week additional comment make beyond prepared remark way possibly size seems like could pretty meaningful sort much assumed kevin herde executive vice president chief financial officer yes key depend fuji customer signing cdmo sort degree separation u would difficult forecast really key partnership country japan notable includes entire portfolio cleancap several cdmos enabled giving hopefully customer opportunity work u particularly later phase flanders open later year need scale need geographic choice reason multiple jurisdiction like say could meaningful depend program able book japanmike ryskin bank america merrill lynch analyst ok right thanks get back queueoperatorour next question come line conor mcnamara rbc capital market please go aheadconor mcnamara rbc capital market analyst hey guy congrats solid quarter look q result came million ahead expecting math correct anything far bulk purchase anything pulled forward worth calling executionkevin herde executive vice president chief financial officer yes would say thanks conor would say one nothing pulled forward think pretty normal quarter u regard kind call drop order meaning thing really funnel customer came really provided upside thinking quarter happens occasionally mostly cleancap certainly maybe enter new phase start new program going order bulk larger order came funnel see happens periodically lead quarterly volatility strong quarter versus internal estimate happy thattrey martin chief executive officer true would add think effort undertaken past quarter commercial execution fruit saw good traction commercial team really getting cleancap opportunity another offering front customer base forwardleaning waykevin herde executive vice president chief financial officer think talked last year reticence committed order takeorpay type arrangement also largely dissipate pandemic sort upside positive consequence people necessarily committing take pay still needing material reason kevin said funnel able take execute within quarterconor mcnamara rbc capital market analyst got great relates guidance looking said first half versus second half revenue implies second half roughly million million quarter second half expect ebitda margin would roughly line second half guy year headwind tailwind would make much followon good place start think beyond kevin herde executive vice president chief financial officer yes think got exactly right conor obviously move type revenue performance saw fourth quarter strong ebitda margin exiting year think around revenue level certainly expect pull slightly lower margin see first half average guidance yearconor mcnamara rbc capital market analyst great thanks guy appreciate itoperatorour next question come line matt sykes goldman sachs please go aheadunknown speaker inaudible matt first one customer conversation trending term bioprocessing recovery within different modality called slide basically one modality seeing positive commentary relative otherskevin herde executive vice president chief financial officer well yes interesting question distribution would getting cell platform people using production would say returning back normal bst distortion example mean get technical week inaudible versus ecoli platform slow recovered would say back normal proportion sale multiple modality expressed different cell line really couple click get particular since many cygnus customer also cdmos distributor unfortunately level visibility specific program many kit using certain cell line certain expression map thing like askingdeb hart head investor relation yes think term like cell therapy versus mrna vaccine type modalitiesunknown speaker customer comment like comment trending within modalitiesdrew burch president nucleic acid production yes drew maybe jump think say seen marked difference cell therapy mrna think got engaged customer dialogue front data saw data term growth clinical trial kind near clinical trial underway clinical preclinical trial underway mrna smaller number gene editing number grown quite bit past year forecasted grow upcoming year dialogue would say consistent excited customer traction excited customer signed initiate production u flanders overall would say kind balanced optimism across portfoliounknown speaker ok great super helpful revenue target million taking consideration new guide confident stepup growth necessary order reach targetkevin herde executive vice president chief financial officer yes sure think look math think looking cagr would certainly building business making investment target mind continue focused thing like flanders exception commercial rd innovation etc think growth target unfamiliar look back core business growth grew think sit today look forward maravai versus previous year lot program lot dollar flowing space lot excitement around lot trey alluded capability product opportunity customer involved think something continue focused certainly build footprint strategically said goal right really focused delivering put starting get business returning growthunknown speaker ok great super helpful thank youdeb hart head investor relation operator think time one last question pleaseoperatorand last question come line paul knight keybanc please go aheadpaul knight keybanc capital market analyst yes thanks time look various biotechnology firm dedicated capping technology agnostic really look alternativestrey martin chief executive officer yes think anyone insightful question way anyone starting new program ideally discovery looking best technology time think extent given customer may agnostic moment time certainly favorite depends whether producing partner partner mentioned comment standard workflow really efficiently incorporates cotranscriptional cap sorry sorry plane going overhead also quite efficient quick would say though people dedicated customer partly reason excited continue innovating adding new option menu think given stage clinical development always try incorporate best technology recent examplepaul knight keybanc capital market analyst last stage limited really commit phase guessing committed phase rightkevin herde executive vice president chief financial officer think usually case going commit go clinical trial maybe switch little bit later see greatest degree switching product program entering clinic think trey point continue work hard bring new one going help customer optimize program excited cleancap ag cleancap primolmetyl cleancap sa cleancap au product approved point moving along nicely quite bit interest move gmp production one size fit continue try bring innovation customer help program achieve much possibly achievepaul knight keybanc capital market analyst thank youdeb hart head investor relation great well would like thank everyone joining u today several conference coming month hope catch person feel free contact u followup question hope great nightoperatoroperator signoff duration minutescall participantsdeb hart head investor relationstrey martin chief executive officerkevin herde executive vice president chief financial officermatt larew william blair company analystjustin bower deutsche bank analystdrew burch president nucleic acid productioncatherine schultemike ryskin bank america merrill lynch analystconor mcnamara rbc capital market analystunknown speakerpaul knight keybanc capital market analyst mrvi analysis earnings call transcript article transcript conference call produced motley fool strive foolish best may error omission inaccuracy transcript article motley fool assume responsibility use content strongly encourage research including listening call reading company sec filing please see term condition additional detail including obligatory capitalized disclaimer liabilitythe motley fool position stock mentioned motley fool disclosure policy